Sources for --What you need to know about IR to increase SVR

Sources:

Hepatitis C and insulin resistance: steatosis, fibrosis and non-response.

http://scielo.isciii.es/scielo.php?pid=S1130-01082006000800006&script=sci_arttext

Insulin resistance and hepatitis C.

http://www.ncbi.nlm.nih.gov/pubmed/18831405?ordinalpos=31&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Insulin-Resistance in Chronic Hepatitis C patients: New Predictor of Sustained Virological Response Independent of HCV Genotype and Liver Fibrosis Stage.

http://aasld.scientificposters.com/epsAbstract.cfm?id=37

Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin.

http://www.ncbi.nlm.nih.gov/pubmed/18680550?ordinalpos=38&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Insulin Resistance and Hyperinsulinemia. Is hyperinsulinemia the cart or the horse?

http://care.diabetesjournals.org/cgi/content/full/31/Supplement_2/S262

Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.

http://www.ncbi.nlm.nih.gov/pubmed/18702647

Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection.

http://www.ncbi.nlm.nih.gov/pubmed/18477344?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_Discovery_RA&linkpos=1&log$=relatedarticles&logdbfrom=pubmed

Diabetes Mellitus Is Associated with Impaired Response to Antiviral Therapy in Chronic Hepatitis C Infection.

http://www.ncbi.nlm.nih.gov/pubmed/19148751?ordinalpos=10&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Glucose >100 mg/dl Reduces Interferon/RBV SVR

http://www.natap.org/2008/HCV/031008_01.htm

Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.

http://www.ncbi.nlm.nih.gov/pubmed/18164296?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_Discovery_RA&linkpos=2&log$=relatedarticles&logdbfrom=pubmed

Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.

http://www.natap.org/2008/HCV/010708_02.htm

Steatosis, Insulin resistance, Iron overload, Fibrosis and Viral load as negative factors affecting Early (EVR) and Sustained (SVR) Virological Response in patients with Chronic Hepatitis C treated with peginterferon and ribavirin.

http://www.hcvadvocate.org/news/reports/AASLD_2008/Abstracts/Monday_Viral_Hepatitis_am.htm#VH1259

High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C.

http://www.ncbi.nlm.nih.gov/pubmed/18028320?ordinalpos=&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&log$=citationsensor

Is HOMA-IR the best marker of insulin resistance in chronic hepatitis due to HCV infection?

http://www.hcvadvocate.org/news/reports/AASLD_2008/Abstracts/Virology.htm

Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation.

http://www.pharmacychoice.com/News/article.cfm?Article_ID=298258

Therapies to Manage Insulin Resistance Improve Response to Interferon-based Therapy in Chronic Hepatitis C Patients.

http://www.hivandhepatitis.com/2008icr/aasld/docs/112108_a.html

Influence of weight reduction on the effectiveness of combined peginterferon and ribavirin treatment in chronic HCV hepatitis.

http://www.ncbi.nlm.nih.gov/pubmed/19004737?ordinalpos=11&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Effect of Breathwalk on body composition, metabolic and mood state in chronic hepatitis C patients with insulin resistance syndrome.

http://www.ncbi.nlm.nih.gov/sites/entrez

Viral Kinetic Response to 12 Week Treatment with Rosiglitazone in Chronic Hepatitis C, Genotype 1 Patients Who Are Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin.

http://www.hcvadvocate.org/news/reports/AASLD_2008/Abstracts/Preclinical_and_clinical_trials_POSTERS%20TUESDAY%20Nov%204.htm#Tues1870

In Chronic Hepatitis C (HCV), Pretreatment with Thiazolidinediones (TZDs) or Metformin Decreases Insulin Resistance (IR) and HCV Viral Load and Increases Early Virologic Response (EVR).

http://www.hcvadvocate.org/news/reports/AASLD_2008/Abstracts/Preclinical_and_clinical_trials_POSTERS%20TUESDAY%20Nov%204.htm#Tues1891

Metformin with Peginterferon Alfa-2a and Ribavirin in the Treatment of Naïve Genotype 1 Chronic Hepatitis C Patients with Insulin Resistance (TRIC-1): Final Results of a Randomized and Double-Blinded Trial.

http://www.hcvadvocate.org/news/reports/AASLD_2008/Abstracts/Late_Breaking_Abstracts.htm#LBA_LB6

Pioglitazone improves early virologic kinetic response to Peg IFN/RBV combination therapy in hepatitis C genotype 1 naïve patients.

http://www.hcvadvocate.org/news/reports/AASLD_2008/Abstracts/Parallel%20Sessions%20Monday%203%20pm.htm#P167

A Randomized, Double-Blind, Placebo-Controlled Study of PPAR-gamma Agonist Pioglitazone Given in Combination with Peginterferon and Ribavirin in Patients with Genotype-1 Chronic Hepatitis C.

http://www.hcvadvocate.org/news/reports/AASLD_2008/Abstracts/Parallel%20Sessions%20Monday%203%20pm.htm#P167

Whole-Body Insulin Sensitivity Index Is a Highly Specific Predictive Marker for Virological Response to Peginterferon Plus Ribavirin Therapy in Chronic Hepatitis C Patients with Genotype 1b and High Viral Load.

http://www.ncbi.nlm.nih.gov/pubmed/19184426?ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: Differences and similarities

http://www.ncbi.nlm.nih.gov/pubmed/19152451?ordinalpos=9&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease.

http://www.ncbi.nlm.nih.gov/sites/entrez

Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance.

http://www.ncbi.nlm.nih.gov/pubmed/19132131?ordinalpos=13&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

OGTT-derived measures of insulin sensitivity are confounded by factors other than insulin sensitivity itself.

http://www.ncbi.nlm.nih.gov/pubmed/18670420?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_Discovery_RA&linkpos=1&log$=relatedarticles&logdbfrom=pubmed

Insulin sensitivity and beta function in the first-degree relatives of type 2 diabetic patients

http://www.ncbi.nlm.nih.gov/pubmed/15631772?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_Discovery_RA&linkpos=2&log$=relatedarticles&logdbfrom=pubmed

Decreased insulin secretion and insulin sensitivity are associated with liver function in subjects with fasting glucose between 100 and 109 mg/dL

http://www.ncbi.nlm.nih.gov/pubmed/18090240?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_Discovery_RA&linkpos=2&log$=relatedarticles&logdbfrom=pubmed

Menopause, but not age, is an independent risk factor for fasting plasma glucose levels in nondiabetic women.

http://www.ncbi.nlm.nih.gov/pubmed/17213751?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_Discovery_RA&linkpos=3&log$=relatedarticles&logdbfrom=pubmed

Elevated serum gamma-glutamyltransferase levels are independently associated with insulin resistance in non-diabetic subjects.

http://www.ncbi.nlm.nih.gov/pubmed/19264371?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Elevated concentrations of liver enzymes and ferritin identify a new phenotype of insulin resistance: effect of weight loss after gastric banding.

http://www.ncbi.nlm.nih.gov/pubmed/18820980?ordinalpos=&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.SmartSearch&log$=citationsensor

Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance.

http://www.ncbi.nlm.nih.gov/sites/entrez

Insulin resistance and lichen planus in patients with HCV-infectious liver diseases.

http://www.ncbi.nlm.nih.gov/pubmed/18397487?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis.

http://www.ncbi.nlm.nih.gov/pubmed/19065558?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_Discovery_RA&linkpos=1&log$=relatedarticles&logdbfrom=pubmed

Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management.

http://www.ncbi.nlm.nih.gov/pubmed/19140227?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_Discovery_RA&linkpos=1&log$=relatedarticles&logdbfrom=pubmed

Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity.

http://www.ncbi.nlm.nih.gov/pubmed/18990675?ordinalpos=23&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum